NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at the WHO headquarters in Geneva, Switzerland where Dr. Glenn will be part of a session entitled: “Pandemic and Potentially Pandemic Vaccines Developed Using New Technologies.” Dr. Glenn’s presentation is entitled: “Rapid Response during the 2009 (H1N1) Pandemic in Mexico with an Influenza VLP Vaccine.” The presentation will be available at www.novavax.com under the Investors/Events tab after the event.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs it’s cutting edge technology to create next generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary VLP technology and unique disposable system enables rapid vaccine development and production where and when it’s needed, worldwide. For more information about Novavax, please visit www.novavax.com.
SOURCE Novavax, Inc.